Skip to content
POM-V Prescription Required Companion Animal

Fortekor Plus 1.25 mg/2.5 mg Tablets

Active ingredients: Benazepril Hydrochloride, Pimobendan

Form

Tablet

Species

Dogs

Manufacturer

Elanco GmbH

VMD MA No.

52127/5014

What it's used for

should only be used in patients whose clinical signs are successfully controlled by administration of the same doses of the individual components (pimobend...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Cheapest online price

£38.72

from VetMedi

4 online retailers compared

Compare all prices

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Fortekor Plus 1.25 mg/2.5 mg Tablets — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

should only be used in patients whose clinical signs are successfully controlled by
administration of the same doses of the individual components (pimobendan and
benazepril hydrochloride) given concurrently.
Dose and treatment schedule:
This veterinary medicinal product is a fixed combination product which should only be used
in dogs which require both active substances to be administered concomitantly at this fixed
dose.
The recommended dose range for this veterinary medicinal product is 0.25–0.5 mg
pimobendan per kg body weight and 0.5–1 mg benazepril hydrochloride per kg body weight
divided into two daily doses. This veterinary medicinal product should be administered
orally, twice daily 12 hours apart (morning and evening) and approximately 1 hour before
feeding.
The tablets are breakable along the score line.
AN: 02229/2024Page 5 of 8
The table below may be used for guidance.
Strength and number of tablets to be administeredFORTEKOR PLUS 1.25 mg/2.5 mg tablets
Body weight
(kg) of dog
MorningEvening2.5 – 50.50.55 – 1011
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an
augmentation of cardiac output is not possible for functional or anatomical reasons (e.g.
aortic or pulmonary stenosis).
Do not use in cases of hypotension, hypovolaemia, hyponatremia or acute renal failure.
Do not use during pregnancy and lactation (see section 3.7).
Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
Dogs.
Rare
(1 to 10 animals / 10,000
animals treated):
Increased heart rate
Diarrhoea
, Vomiting
1,2
Anorexia
, Lethargy
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Elevated creatinine
Incoordination
Fatigue
1
Moderate. These effects are dose-dependent and can be avoided by reducing the dose in
those cases.
Transient.
At the start of therapy in dogs with chronic kidney disease. A moderate increase in plasma
creatinine concentrations following administration of ACE inhibitors is compatible with the
reduction in glomerular hypertension induced by these agents, and is therefore not
necessarily a reason to stop therapy in the absence of other signs.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either
the marketing authorisation holder or the national competent authority via the national
reporting system. See the package leaflet for respective contact details.
None.

Special precautions for safe use in the target species:
In cases of chronic kidney disease, it is recommended to check the dog’s hydration status
before starting therapy, and to monitor its plasma creatinine and blood erythrocyte counts
during therapy.
As pimobendan is metabolised in the liver, the veterinary medicinal product should not be
administered to dogs with severe hepatic insufficiency.
The efficacy and safety of the veterinary medicinal product has not been established in
dogs below 2.5 kg body weight or under 4 months of age.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Wash hands after use.
AN: 02229/2024Page 3 of 8
People with known hypersensitivity to pimobendan or benazepril hydrochloride should
avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package
leaflet or the label to the physician.
Pregnant women should take special care to avoid accidental oral exposure because
angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child
during pregnancy in humans.
Special precautions for the protection of the environment:
Not applicable.
In dogs with congestive heart failure, benazepril hydrochloride and pimobendan have been
given in combination with digoxin and diuretics without demonstrable adverse interactions.
In pharmacological studies no interaction between the cardiac glycoside ouabain and
pimobendan was detected. The pimobendan-induced increase in contractility of the heart is
attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist
propranolol.
In man, the combination of angiotensin converting enzyme (ACE) inhibitors and non-
steroidal anti- inflammatory drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy
or impaired renal function. Therefore, the concurrent use of the veterinary medicinal
product with NSAIDs or any other medications with a hypotensive effect should be
considered carefully before using such combinations.
The combination of the veterinary medicinal product and other anti-hypertensive agents
(e.g. calcium channel blockers, -blockers or diuretics), anaesthetics or sedatives may lead
to additive hypotensive effects. Renal function and signs of hypotension (lethargy,
weakness, etc) should be monitored closely and treated as necessary.
Interactions with potassium-sparing diuretics such as spironolactone, triamterene or
amiloride cannot be ruled out. It is therefore recommended to monitor plasma potassium
levels when using the veterinary medicinal product in combination with a potassium sparing
diuretic because of the risk of hyperkalemia.
Store below 25 C.
Keep the blister in the outer carton in order to protect from moisture.
Any remaining half tablet should be placed back in the opened blister and stored (for a
maximum of 1 day) in the original cardboard carton.
Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Price comparison

Fortekor Plus 1.25 mg/2.5 mg Tablets Prices by Online retailer

Fortekor Plus 1.25 mg/2.5 mg Tablets is a prescription-only veterinary medicine (POM-V). Prices are listed for information, with every retailer shown on equal terms. To buy it online you need a written prescription from your vet, which the retailer will ask for at checkout. Under the CMA Order your vet must provide one on request, with the fee capped at £21 from 2027. Your prescription rights →

Price Comparison

VetMedi
£38.72
Trustpilot: 4.9/5 (3,295 reviews) · 30
In stock
VetUK
£39.49
Trustpilot: 4.0/5 (25,586 reviews) · 30
In stock
Animed Direct
£39.99
Trustpilot: 4.6/5 (354,000 reviews) · 30
In stock
Pet Drugs Online
£42.49
Trustpilot: 2.5/5 (500 reviews) · 30
In stock

Prices last checked: 7 months ago. Prices may vary. Always confirm with the online retailer before ordering.

We may earn a commission when you buy through our links, at no extra cost to you.

Never miss a renewal

Create a free account to track Fortekor Plus 1.25 mg/2.5 mg Tablets, set reminders, and compare prices across online retailers.

Sign up free

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.